ORIGIMM Biotechnology Austria

ORIGIMM is a young, ambitious Austrian biotech company striving to become a market leader in the treatment of acute and chronic infectious diseases, and dermatological conditions associated with various pathogens.

ORIGIMM is developing the worldwide first therapeutic vaccine for treatment of acne vulgaris; the disease with enormous market potential, afflicting 85% of teenagers and more than 20% of adults below 40 years of age.

Using its proprietary ProVaDis® technology platform ORIGIMM overcomes the challenges in vaccine and immune therapy development by early focus on protective efficacy of antigens in the context of human disease. This translates into a rapid selection of best, most protective candidates with a significantly improved success in clinical trials. ProVaDis platform enables ORIGIMM to rapidly build its product portfolio in many other lucrative areas.

Website:
www.origimm.com
Year Founded
2014 (Seed phase/LLC), 2012 (pre-Seed,o.p.)
Biotech Subsector
Biotech Phase of Development
Technology Overview
Proprietary functional immunologic screening platform which enables rapid and reliable identification of best antigens and vaccine or mAb candidates.
Alliance & Collaborations
Clinicians and scientific KOLs. Initiation stage (pharmaceutical companies).
Supporting Metrics or Evidence
Proof of principle completed; priority patent application submitted and approved, high industrial interest
Current Financing Needs
$1.5 M
Current Timeline
Acne vaccine clinical phase start (2017). Vaccine candidate antigens against second indication selected (2017).
Current Investors
No private investors yet. Financed by the founders and public funds.
IP Status
Technology patent priority date 2014 (2015). Acne vaccine antigens patent pending (Q1/2015).
Recent Milestones
Technology POC completed. Acne vaccine candidates identified. Successful fund raising from several public research institutions supporting high technology development.
Management Team Highlights
Sanya SELAK, PhD – Founder, inventor and CEO. 20+ years of international scientific and industrial experience in antigen discovery, validation and immunology. Author of many publications, recipient of many scientific and funding awards and inventor on several patents. Tamás BERKE MD, MSc – Co-founder and COO. Physician, trained in pediatric infectious diseases, molecular virology, and a biotech professional with 20+ years of scientific and industry experience in project management during all stages of pre-clinical and clinical vaccine development. Thomas FISCHER MBA – CFO. Serial entrepreneur since his university degree 25 years ago. Thomas has dedicated know-how and experience in strategy building, fundraising, business and corporate development, finance and administrative affairs.
Dr Sanya Selak
Dr Sanya Selak
LinkedIn logo CEO 

Recardio Austria

RECARDIO is a virtual, private, clinical stage life science company founded in 2011 focusing on drug based regenerative therapeutic modalities for the treatment of cardiovascular diseases.

The company started product development mid-stage by taking advantage of >$100m of previously invested capital in the licensed lead compound, Dutogliptin. Safety has been established in more than 1000 subjects and all non-clinical studies have been completed to the highest standards, including 2 year carcinogenicity, resulting in a de-risked clinical development program from the safety perspective and overall reduction in total program costs.

 After completion of limited preclinical studies clinical trials will commence in early 2015 in patients with acute myocardial infarction.



After establishing proof-of-principle in vivo and completion of the preclinical development, it has entered clinical stage and is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.

Website:
www.recardio.eu
Year Founded
2011
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Current Financing Needs
Series A in process
Current Timeline
Phase 2b starting in 2015
Current Investors
Private
IP Status
Issued use and composition of matter patents
Recent Milestones
Positive FDA advice in 12.2014
Roman Schenk
CEO